OmniAb, Inc. reported its financial results for the first quarter ended March 31, 2025, on May 8, 2025. Total revenue for Q1 2025 was $4.2 million, an increase from $3.8 million in Q1 2024, driven by a $1.0 million Phase 1 milestone payment and higher license fees.
The company posted a net loss of $18.2 million, or $0.17 per share, for Q1 2025, compared to a net loss of $19.0 million, or $0.19 per share, in the prior year period. OmniAb affirmed its 2025 revenue guidance of $20 million to $25 million and revised its operating expense guidance to $85 million to $90 million, down from the previous range of $90 million to $95 million.
OmniAb also announced the launch of the xPloration Partner Access Program, allowing current partners to purchase the xPloration instrument for their own laboratories. This proprietary, high-throughput single B-cell screening platform leverages machine learning and artificial intelligence to enhance antibody discovery.
The xPloration program is expected to create new, accretive revenue streams for OmniAb from instrument sales, proprietary consumables, and software subscriptions. This initiative enhances the scalability of OmniAb's technology platforms and diversifies its business opportunities.
Operationally, OmniAb entered into three new platform license agreements in Q1 2025, including with the Wyss Institute at Harvard University, Takis Biotech S.r.l., and Orion Corporation. As of March 31, 2025, the company had 95 active partners and 378 active programs, with 33 OmniAb-derived programs in clinical development or commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.